Inadequate use of antibiotics in the covid-19 era: effectiveness of antibiotic therapy

Bendala Estrada, A.D. ; Calderón Parra, J. ; Fernández Carracedo, E. ; Muiño Míguez, A. ; Ramos Martínez, A. ; Muñez Rubio, E. ; Rubio-Rivas, M. ; Agudo, P. ; Arnalich Fernández, F. ; Estrada Perez, V. ; Taboada Martínez, M.L. ; Crestelo Vieitez, A. (Universidad de Zaragoza) ; Pesqueira Fontan, P.M. ; Bustamante, M. ; Freire, S.J. ; Oriol-Bermúdez, I. ; Artero, A. ; Olalla Sierra, J. ; Areses Manrique, M. ; Carrasco-Sánchez, H.F.J. ; Vento, V.C. ; García García, G.M. ; Cubero-Morais, P. ; Casas-Rojo, J.-M. ; Núñez-Cortés, J.M.

Resumen: Background: Since December 2019, the COVID-19 pandemic has changed the concept of medicine. This work aims to analyze the use of antibiotics in patients admitted to the hospital due to SARS-CoV-2 infection. Methods: This work analyzes the use and effectiveness of antibiotics in hospitalized patients with COVID-19 based on data from the SEMI-COVID-19 registry, an initiative to generate knowledge about this disease using data from electronic medical records. Our primary endpoint was all-cause in-hospital mortality according to antibiotic use. The secondary endpoint was the effect of macrolides on mortality. Results: Of 13, 932 patients, antibiotics were used in 12, 238. The overall death rate was 20.7% and higher among those taking antibiotics (87.8%). Higher mortality was observed with use of all antibiotics (OR 1.40, 95% CI 1.21–1.62; p <.001) except macrolides, which had a higher survival rate (OR 0.70, 95% CI 0.64–0.76; p <.001). The decision to start antibiotics was influenced by presence of increased inflammatory markers and any kind of infiltrate on an x-ray. Patients receiving antibiotics required respiratory support and were transferred to intensive care units more often. Conclusions: Bacterial co-infection was uncommon among COVID-19 patients, yet use of antibiotics was high. There is insufficient evidence to support widespread use of empiric antibiotics in these patients. Most may not require empiric treatment and if they do, there is promising evidence regarding azithromycin as a potential COVID-19 treatment. © 2021, The Author(s).

Idioma: Inglés

DOI: 10.1186/s12879-021-06821-1

Año: 2021

Publicado en: BMC Infectious Diseases 21 (2021), 1144 [23 pp.]
ISSN: 1471-2334

Factor impacto JCR: 3.669 (2021)

Categ. JCR: INFECTIOUS DISEASES rank: 60 / 96 = 0.625 (2021) - Q3 - T2

Factor impacto CITESCORE: 4.8 - Medicine (Q2)

Factor impacto SCIMAGO: 1.042 - Infectious Diseases (Q2)

Tipo y forma: Article (Published version)

Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)